303 related articles for article (PubMed ID: 7750284)
21. Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene.
Hammond GL; Bocchinfuso WP; Orava M; Smith CL; van den Ende A; van Enk A
Contraception; 1994 Oct; 50(4):301-18. PubMed ID: 7813219
[TBL] [Abstract][Full Text] [Related]
22. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.
Muhn P; Fuhrmann U; Fritzemeier KH; Krattenmacher R; Schillinger E
Ann N Y Acad Sci; 1995 Jun; 761():311-35. PubMed ID: 7625729
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of desogestrel.
McClamrock HD; Adashi EY
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1021-8. PubMed ID: 8447355
[TBL] [Abstract][Full Text] [Related]
24. Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
Bergink W; Assendorp R; Kloosterboer L; van Lier W; Voortman G; Qvist I
Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2132-7. PubMed ID: 2147817
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological effect of halogen substituted phenyl acetic acid derivatives of progesterone as potent progesterone receptor antagonists.
Cabeza M; Bratoeff E; Gómez G; Heuze I; Rojas A; Ochoa M; Palomino MA; Revilla C
J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):232-9. PubMed ID: 18625316
[TBL] [Abstract][Full Text] [Related]
26. Steroid receptor profiling of vinclozolin and its primary metabolites.
Molina-Molina JM; Hillenweck A; Jouanin I; Zalko D; Cravedi JP; Fernández MF; Pillon A; Nicolas JC; Olea N; Balaguer P
Toxicol Appl Pharmacol; 2006 Oct; 216(1):44-54. PubMed ID: 16750840
[TBL] [Abstract][Full Text] [Related]
27. Selectivity information on desogestrel.
Collins D
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1010-6. PubMed ID: 8447353
[TBL] [Abstract][Full Text] [Related]
28. The selectivity of a new progestin.
Phillips A
Acta Obstet Gynecol Scand Suppl; 1990; 152():21-4. PubMed ID: 2189281
[TBL] [Abstract][Full Text] [Related]
29. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
[TBL] [Abstract][Full Text] [Related]
30. New knowledge in the physiology of hormonal contraceptives.
Lobo RA; Stanczyk FZ
Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1499-507. PubMed ID: 8178898
[TBL] [Abstract][Full Text] [Related]
31. Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives.
Schoonen WG; Deckers GH; de Gooijer ME; de Ries R; Kloosterboer HJ
J Steroid Biochem Mol Biol; 2000 Nov; 74(4):213-22. PubMed ID: 11162927
[TBL] [Abstract][Full Text] [Related]
32. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene].
Belaisch J; Hommais-loufrani B
Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078
[TBL] [Abstract][Full Text] [Related]
33. The pharmacological profile of a novel norpregnance progestin (trimegestone).
Philibert D; Bouchoux F; Degryse M; Lecaque D; Petit F; Gaillard M
Gynecol Endocrinol; 1999 Oct; 13(5):316-26. PubMed ID: 10599548
[TBL] [Abstract][Full Text] [Related]
34. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene.
Guengerich FP
Chem Res Toxicol; 1990; 3(4):363-71. PubMed ID: 2133086
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of the influence of the high-mobility group box 1 protein on DNA binding and transcriptional activation by the androgen, glucocorticoid, progesterone and mineralocorticoid receptors.
Verrijdt G; Haelens A; Schoenmakers E; Rombauts W; Claessens F
Biochem J; 2002 Jan; 361(Pt 1):97-103. PubMed ID: 11742533
[TBL] [Abstract][Full Text] [Related]
36. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
Chez RA
Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1296-300. PubMed ID: 2524163
[TBL] [Abstract][Full Text] [Related]
37. The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel.
Orme M; Back DJ; Ward S; Green S
Contraception; 1991 Apr; 43(4):305-16. PubMed ID: 1830266
[TBL] [Abstract][Full Text] [Related]
38. Desogestrel versus gestodene in oral contraceptives: influence on the clinical and histomorphological features of benign breast disease.
Di Lieto A; De Rosa G; Albano G; Pagnano AM; Campanile M; Terracciano L; Pontillo M; Cimmino E; Covelli A; Paladini A
Eur J Obstet Gynecol Reprod Biol; 1994 May; 55(1):71-83. PubMed ID: 7958144
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.
Kuhnz W; Schütt B; Power J; Back DJ
Arzneimittelforschung; 1992 Sep; 42(9):1139-41. PubMed ID: 1445482
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
